QuidelOrtho is an attractively valued diagnostics company with a forward P/E of 6.0x and a strong recent earnings track record, but high short interest of 24%, declining revenue of -10%, and a market cap below the $1 billion investable threshold create significant headwinds that must be resolved before the value opportunity can be realized.
Thesis pillars
- Below Investable Market Cap↓Deteriorating
- Deep Value Forward Pe→Stable
- Earnings Beat Streak Recovery→Stable
- +1 more pillar — see the Why tab for full reasoning
QuidelOrtho Corporation (QDEL) Stock Analysis
Inst Constrain edge
Healthcare · Medical Devices
Sell if holding. Engine safety override at $16.57: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 24%; Elevated put/call ratio: 1.33; Below-average business quality.
QuidelOrtho develops and sells in-vitro diagnostic instruments and tests across four business units — Labs, Molecular Diagnostics, Point of Care, and Transfusion Medicine — serving customers in more than 140 countries through direct sales and distributors. Respiratory... Read more
Sell if holding. Engine safety override at $16.57: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 24%; Elevated put/call ratio: 1.33; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 4/9 gates (clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA) and earnings proximity 7d<=7d. Suitability: speculative.
Recent developments
updated 2026-07-31Recent Developments — QuidelOrtho Corporation
Latest news
- NEWS Citigroup Maintains Neutral on QuidelOrtho, Raises Price Target to $18 — benzinga Jul 8, 2026 neutral
- NEWS JP Morgan Maintains Underweight on QuidelOrtho, Raises Price Target to $12 — benzinga Jul 1, 2026 neutral
- NEWS 12 Health Care Stocks Moving In Monday's Intraday Session — benzinga Jun 29, 2026 neutral
- NEWS Iridium Communications, FuelCell Energy, Rocket Lab And Other Big Stocks Moving Higher On Monday — benzinga Jun 29, 2026 neutral
- NEWS QuidelOrtho Appoints Micah Young As CFO, Effective July 6, Succeeding Joseph Busky — benzinga Jun 23, 2026
Generated 2026-07-31T02:43:38Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWProductrespiratory products15%10-K Item 1A: 'sales of our respiratory products accounted for approximately 15% of our total revenues for the year ended December 28, 2025'
- HIGHSuppliersingle and sole source suppliers10-K Item 1A: 'our reliance on a small number of contract manufacturers and a large number of single and sole source suppliers'
- MEDIUMCustomerkey distributors10-K Item 1A: 'we rely on certain key distributors for the sales of some of our products'
Material Events(8-K, last 90d)
- 2026-06-23Item 5.02MEDIUMBoard appointed Micah Young as CFO effective July 6, 2026, succeeding Joseph M. Busky, who previously announced plans to retire (disclosed February 13, 2026). Busky continues in his role through the effective date under a transition and retirement agreement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Unprofitable operations — net margin -45.6%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $16.57: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 24%; Elevated put/call ratio: 1.33; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $15.41. Score 5.2/10, moderate confidence.
Take-profit target: $17.43 (+5.2% upside). Prior stop was $15.41. Stop-loss: $15.41.
Concentration risk — Supplier: single and sole source suppliers; Quality below floor (2.8 < 4.0).
QuidelOrtho Corporation trades at a P/E of N/A (forward 6.7). TrendMatrix value score: 8.6/10. Verdict: Sell.
10 analysts cover QDEL with a consensus score of 2.5/5. Average price target: $21.
What does QuidelOrtho Corporation do?QuidelOrtho develops and sells in-vitro diagnostic instruments and tests across four business units — Labs, Molecular...
QuidelOrtho develops and sells in-vitro diagnostic instruments and tests across four business units — Labs, Molecular Diagnostics, Point of Care, and Transfusion Medicine — serving customers in more than 140 countries through direct sales and distributors. Respiratory diagnostics products, including the QuickVue and Sofia platforms, accounted for approximately 15% of total revenue in fiscal 2025, while the company winds down its U.S. donor-screening portfolio, expected substantially complete by the first half of 2026.